REP PROFILE
REP PROFILE
Brent Meeks
Company
Forrest Pharmaceuticals
Title
Medical Sales Representative
Current home
Redding, CA
Territory:Â Northern California
Customers:Â Pulmonologists, cardiologists, OB/GYNs, general practitioners and urologists.
Awards:Â Outstanding sales achievement, regional rep of the year and eight quarterly awards.
Sales techniques:Â "I try to involve the doctor in the sale. I ask questions to find out what the physician wants to know. I also identify the doctor's personality and develop a presentation that appeals to that personality type."
Motivation:Â "I love to educate people. Pharmaceutical sales allows me the opportunity to teach physicians and their staff about the products I sell. I also like knowing that people benefit from my products. I'm not just doing a job, I'm affecting lives in a positive way."
Being a team player:Â "My co-workers and I have developed a trust which allows us to confide in one another. This trust and respect allows us to share our sales techniques and ideas with one another. Also, our regional manager is concerned about our lives. He treats us as friends, not just employees."
Work and family:Â "I keep work and home separate. When I have paperwork that needs to be done, I do it early in the morning or after the children have gone to bed. I also have a large territory. I will get up earlier to drive to my destination so I can return to my home in the evening. My firm foundation at home helps to me keep a firm foundation at work."
Three qualities a rep needs to succeed:Â "Integrity, the ability to communicate and humility."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.